AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in rat models of nociceptive pain

• Published in: Neurological research (New York) 2015-06, Vol.37 (6), p.525-530
• Main Authors: Murai, Nobuhito, Takeshita, Nobuaki, Nishigaki, Fusako, Irie, Megumi, Tamura, Seiji, Aoki, Toshiaki, Matsuoka, Nobuya
• Format: Article
• Language: English
• Subjects: Analgesics - blood; Analgesics - pharmacology; Animals; Arthralgia - drug therapy; Arthralgia - physiopathology; Arthritis; Arthritis, Experimental - drug therapy; Arthritis, Experimental - physiopathology; AS1069562; Bradykinin; Chronic Disease; Disease Models, Animal; Duloxetine; Duloxetine Hydrochloride - pharmacology; Female; Male; Morpholines - blood; Morpholines - pharmacology; Nociceptive pain; Nociceptive Pain - drug therapy; Nociceptive Pain - physiopathology; Pain Measurement; Rats, Inbred Lew; Rats, Sprague-Dawley; Serotonin and norepinephrine reuptake inhibitor; Time Factors
• ISSN: 0161-6412; 1743-1328
• DOI: 10.1179/1743132815Y.0000000007

Objectives: The (+)-isomer of indeloxazine AS1069562 has multiple pharmacological actions, such as serotonin (5-HIT) and norepinephrine (NE) reuptake inhibition and analgesic effects in animal models of neuropathic pain. Here, we investigated the analgesic effects of AS1069562 in rat models of inflammatory and noninflammatory nociceptive pain. Methods: Adjuvant-induced arthritis (AIA) and bradykinin-induced knee joint pain were used as rat models of inflammatory pain. The chronic phase of monoiodoacetate-induced arthritis (MIA) was used as a rat model of noninflammatory pain. Analgesic effects were evaluated by weight-bearing deficit in the AIA and MIA models and by pain response in the bradykinin-induced knee joint pain model. Results: In the AIA model and the bradykinin-induced knee joint pain model, AS1069562 significantly ameliorated the pain-related behavior of weight-bearing deficit and the pain response, respectively. AS1069562 also significantly improved the pain-related behavior of weight-bearing deficit in the chronic phase of the MIA model. Further, following monoiodoacetate injection, repeated administration of AS1069562 or duloxetine significantly improved weight-bearing deficit in the MIA model. Interestingly, the analgesic effect of AS1069562 was sustained for 24 hours after the last administration, although the plasma concentration of AS1069562 was reduced to undetectable levels. In contrast, the analgesic effect of duloxetine did not continue after treatment discontinuation. Discussion: AS1069562 exerts analgesic effects on inflammatory and noninflammatory nociceptive pain in rat models of arthritis pain, and repeated administration of AS1069562 exerts a more persistent analgesic effect on arthritis pain than duloxetine. These findings suggest that AS1069562 has an attractive analgesic profile for the treatment of nociceptive pain.